Objective 5 and Deliverables of WP5

Α Cdc6 construct [CAG-loxP-eGFP-STOP-loxp-Cdc6-IRES-βGal (CAG-Cdc6)] was injected in zygote pronuclei. Following implantation in pseudopregnant females resulted in generation of the first known CAG-Cdc6 founders. Currently, these founders are undergoing crossings with C57BL/6J mice to obtain the CAG-Cdc6 mouse model. These mice will be crossed with whole body or tissue specific Cre animals to obtain corresponding Cdc6 overexpressing animal models.



VG New

Prof. Vassilis G. Gorgoulis

Laboratory of Histology-Embryology
Molecular Carcinogenesis Group
Medical School
National and Kapodistrian University of Athens



Chair of Clinical Molecular Pathology,

Ninewells Hospital and School of Medicine


University of Dundee, Dundee, UK


Biomedical Research Foundation of the Academy of Athens


Faculty Institute for Cancer Sciences, University of Manchester,
Manchester Academic Health Science Centre, Manchester, UK

Manchester Centre for Cellular Metabolism,
University of Manchester, Manchester Academic Health Science Centre, Manchester


EMBO member


European Academy
of Cancer Sciences member


Academia Europaea member


Intelligencia.ai, 180 Varick Street, 6th Floor, New York, NY 10014, USA 






Office Tel: 0030 210-7462352
Fax: 0030 210-7462340
E-mail: vgorg@med.uoa.gr


Error: No articles to display

Also see...


Copyright ©2011-2015, Prof. Gorgoulis Powered by AVMap